Immediate Impact

1 by Nobel laureates 62 standout
Sub-graph 1 of 22

Citing Papers

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
2024 Standout
2 intermediate papers

Works of Yshai Yavin being referenced

Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
2021
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
2021

Author Peers

Author Last Decade Papers Cites
Yshai Yavin 253 95 65 97 20 333
Susanne Jung 180 78 162 67 30 343
Donna Shu‐Han Lin 182 77 80 52 25 273
Bai Chang 128 38 39 67 23 327
Anastasia Ustyugova 266 78 110 93 31 369
Alain Gay 171 81 137 49 21 338
Zhenwei Fang 211 109 46 94 14 307
Maria Toumpourleka 126 50 101 81 23 331
Sophie Girerd 157 88 70 62 19 317
Takehiro Kawata 180 51 33 77 14 364
A Okša 82 28 68 49 20 328

All Works

Loading papers...

Rankless by CCL
2026